2,4-thiazolidinedione has been researched along with Obesity in 53 studies
thiazolidine-2,4-dione: structure in first source
1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Long-term (2 weeks) oral treatment with the rexinoids LG100268 and LG100324 reduced food intake and body weight gain, whereas rosiglitazone (BRL49653) tended to increase both food intake and weight gain." | 7.70 | The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat. ( Cawthorne, MA; Emilsson, V; Heyman, R; Liu, YL; O'Dowd, J; Sennitt, M; Wang, S, 2000) |
| "Both metformin and thiazolidinedione derivatives(TZDs) improve insulin resistance, a major pathogenesis of type 2 diabetes, and decrease blood glucose levels without stimulating insulin secretion." | 4.82 | [Insulin-sensitizing agents: metformin and thiazolidinedione derivatives]. ( Satoh, J, 2003) |
| " In impaired glucose tolerance subjects, these procedures were performed before and after treatment with pioglitazone or metformin." | 3.74 | Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. ( Bodles, AM; Fried, SK; Kern, LM; Kern, PA; Lee, MJ; McGehee, RE; Phanavanh, B; Rasouli, N; Spencer, HJ; Starks, T; Varma, V; Yao-Borengasser, A, 2007) |
| "Combination of insulin and rosiglitazone is effective in massively obese patients with Type 2 diabetes, though there is a high incidence of peripheral oedema." | 3.71 | Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes. ( Akarca, C; Barton, DM; Baskar, V; Buch, HN; Kamalakannan, D; Singh, BM, 2002) |
| " Long-term (2 weeks) oral treatment with the rexinoids LG100268 and LG100324 reduced food intake and body weight gain, whereas rosiglitazone (BRL49653) tended to increase both food intake and weight gain." | 3.70 | The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat. ( Cawthorne, MA; Emilsson, V; Heyman, R; Liu, YL; O'Dowd, J; Sennitt, M; Wang, S, 2000) |
| "The outcomes were liver biopsy-based (NAFLD activity score [NAS], fibrosis stage, and NASH resolution), noninvasive technique-based (liver fat content on proton magnetic resonance spectroscopy [1H-MRS] and controlled attenuation parameter [CAP]), biological, and anthropometric indicators." | 3.01 | Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis. ( Kim, H; Kim, K; Kim, MG; Park, MJ, 2023) |
| "Pioglitazone treatment led to a significant 3% body mass increase." | 2.90 | Effect of pioglitazone treatment on brown adipose tissue volume and activity and hypothalamic gliosis in patients with type 2 diabetes mellitus: a proof-of-concept study. ( Cendes, F; Cintra, RM; de-Lima-Júnior, JC; Folli, F; Monfort-Pires, M; Rachid, B; Ramos, CD; Rodovalho, S; Van de Sande-Lee, S; Velloso, LA, 2019) |
| "Pioglitazone treatment improves insulin resistance (IR), glucose metabolism, hepatic steatosis, and necroinflammation in patients with nonalcoholic steatohepatitis (NASH)." | 2.74 | Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. ( Balas, B; Belfort-Aguilar, R; Cusi, K; Gastaldelli, A; Hardies, LJ; Harrison, SA; Schenker, S, 2009) |
| "Weight loss is the best treatment option, which can be a challenging task for patients to achieve and maintain." | 2.46 | Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management. ( Brown, A; Desai, M; Taneja, D; Tannock, LR, 2010) |
| "Insulin resistance is defined as a state of subnormal biological response to normal quantity of insulin." | 2.43 | [Insulin resistance: the adipose tissue in the focus]. ( Urich, E, 2005) |
| "Type 2 diabetes mellitus is a major cause of morbidity and mortality worldwide, and the prevalence is set to increase dramatically over the coming decades." | 2.43 | Etiology of insulin resistance. ( Petersen, KF; Shulman, GI, 2006) |
| "Insulin resistance is associated with VAT products, such as free fatty acids and their metabolites, as well as cytokines, such as tumour necrosis factor alpha (TNF-alpha)." | 2.42 | The relationship of obesity to the metabolic syndrome. ( Lebovitz, HE, 2003) |
| "Current clinical management of type 2 diabetes is focused on treatment of the signs and symptoms of late-stage disease rather than addressing potential underlying causes, which may be amenable to currently available therapies, based on a broad understanding of existing data, practice experience, and rational speculation." | 2.42 | Pancreatic beta-cell loss and preservation in type 2 diabetes. ( Buchanan, TA, 2003) |
| "For now, the goals and methods of treating hypertension and dyslipidemia are the same in people with the metabolic syndrome as in the general population." | 2.41 | A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia. ( Hoogwerf, BJ; Nambi, V; Sprecher, DL, 2002) |
| "Insulin resistance is associated with many common diseases including diabetes mellitus, hyperlipidemia and hypertension, and plays an important role for determining their clinical courses." | 2.41 | [Insulin resistance and cytokine, cytokine receptor]. ( Hamaguchi, T; Hanafusa, T; Matsuzawa, Y; Nakajima, H, 2000) |
| "Obesity is frequently associated with excess caloric fat dietary intake, especially in the form of fatty acids." | 2.41 | Pharmacological treatment of insulin resistance in obesity. ( Camejo, G; Ljung, B; Oakes, N, 2001) |
| " However, their use has been curtailed by substantial adverse effects on weight, bone, heart, and hemodynamic balance." | 1.48 | PPARγ deacetylation dissociates thiazolidinedione's metabolic benefits from its adverse effects. ( Area-Gomez, E; Chan, M; Creusot, RJ; Fan, L; Fu, W; Ji, R; Kon, N; Kraakman, MJ; Larrea, D; Liu, Q; Namwanje, M; Postigo-Fernandez, J; Qiang, L, 2018) |
| "A 50-year-old obese white man with type 2 diabetes presented with cardiogenic shock." | 1.32 | Thiazolidinedione-induced congestive heart failure. ( Cheng, AY; Fantus, IG, 2004) |
| "Diabetes mellitus is a chronic disease that leads to complications including heart disease, stroke, kidney failure, blindness and nerve damage." | 1.31 | The hormone resistin links obesity to diabetes. ( Ahima, RS; Bailey, ST; Banerjee, RR; Bhat, S; Brown, EJ; Lazar, MA; Patel, HR; Steppan, CM; Wright, CM, 2001) |
| "Insulin resistance is a characteristic feature of type 2 diabetes and obesity." | 1.31 | Lipid lowering explains the insulin sensitivity enhancing effects of a thiazolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione. ( Johnson, WT; Stephens, TW; Yakubu-Madus, FE, 2000) |
| "Rosiglitazone treatment normalized the insulin resistance and restored GLUT4 protein levels in obese rat hearts." | 1.31 | Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. ( Buckingham, RE; Clarke, K; Cole, MA; Desrois, M; Draper, NJ; Sidell, RJ, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (7.55) | 18.2507 |
| 2000's | 37 (69.81) | 29.6817 |
| 2010's | 9 (16.98) | 24.3611 |
| 2020's | 3 (5.66) | 2.80 |
| Authors | Studies |
|---|---|
| Benova, A | 1 |
| Ferencakova, M | 1 |
| Bardova, K | 1 |
| Funda, J | 1 |
| Prochazka, J | 1 |
| Spoutil, F | 1 |
| Cajka, T | 1 |
| Dzubanova, M | 1 |
| Balcaen, T | 1 |
| Kerckhofs, G | 1 |
| Willekens, W | 1 |
| van Lenthe, GH | 1 |
| Alquicer, G | 1 |
| Pecinova, A | 1 |
| Mracek, T | 1 |
| Horakova, O | 1 |
| Rossmeisl, M | 1 |
| Kopecky, J | 1 |
| Tencerova, M | 1 |
| Park, MJ | 1 |
| Kim, H | 1 |
| Kim, MG | 1 |
| Kim, K | 1 |
| de-Lima-Júnior, JC | 1 |
| Rodovalho, S | 1 |
| Van de Sande-Lee, S | 1 |
| Monfort-Pires, M | 1 |
| Rachid, B | 1 |
| Cintra, RM | 1 |
| Ramos, CD | 1 |
| Cendes, F | 1 |
| Folli, F | 1 |
| Velloso, LA | 1 |
| Benson, KK | 1 |
| Hu, W | 1 |
| Weller, AH | 1 |
| Bennett, AH | 1 |
| Chen, ER | 1 |
| Khetarpal, SA | 1 |
| Yoshino, S | 1 |
| Bone, WP | 1 |
| Wang, L | 1 |
| Rabinowitz, JD | 1 |
| Voight, BF | 1 |
| Soccio, RE | 1 |
| Shannon, CE | 1 |
| Ragavan, M | 1 |
| Palavicini, JP | 1 |
| Fourcaudot, M | 1 |
| Bakewell, TM | 1 |
| Valdez, IA | 1 |
| Ayala, I | 1 |
| Jin, ES | 1 |
| Madesh, M | 1 |
| Han, X | 1 |
| Merritt, ME | 1 |
| Norton, L | 1 |
| Chitturi, S | 1 |
| Wong, VW | 1 |
| Chan, WK | 1 |
| Wong, GL | 1 |
| Wong, SK | 1 |
| Sollano, J | 1 |
| Ni, YH | 1 |
| Liu, CJ | 1 |
| Lin, YC | 1 |
| Lesmana, LA | 1 |
| Kim, SU | 1 |
| Hashimoto, E | 1 |
| Hamaguchi, M | 1 |
| Goh, KL | 1 |
| Fan, J | 1 |
| Duseja, A | 1 |
| Dan, YY | 1 |
| Chawla, Y | 1 |
| Farrell, G | 1 |
| Chan, HL | 1 |
| Kraakman, MJ | 1 |
| Liu, Q | 1 |
| Postigo-Fernandez, J | 1 |
| Ji, R | 1 |
| Kon, N | 1 |
| Larrea, D | 1 |
| Namwanje, M | 1 |
| Fan, L | 1 |
| Chan, M | 1 |
| Area-Gomez, E | 1 |
| Fu, W | 1 |
| Creusot, RJ | 1 |
| Qiang, L | 1 |
| Sone, Y | 1 |
| Hirasawa, R | 1 |
| Ichi, I | 1 |
| Ishikawa, T | 1 |
| Kodama, S | 1 |
| Sone, H | 1 |
| Egawa, S | 1 |
| Kawahara, K | 1 |
| Otsuka, Y | 1 |
| Fujiwara, Y | 1 |
| Walton, RG | 1 |
| Zhu, B | 1 |
| Unal, R | 2 |
| Spencer, M | 1 |
| Sunkara, M | 1 |
| Morris, AJ | 1 |
| Charnigo, R | 1 |
| Katz, WS | 1 |
| Daugherty, A | 1 |
| Howatt, DA | 1 |
| Kern, PA | 3 |
| Finlin, BS | 1 |
| Gastaldelli, A | 1 |
| Harrison, SA | 1 |
| Belfort-Aguilar, R | 1 |
| Hardies, LJ | 1 |
| Balas, B | 1 |
| Schenker, S | 1 |
| Cusi, K | 1 |
| Brown, A | 1 |
| Desai, M | 1 |
| Taneja, D | 1 |
| Tannock, LR | 1 |
| Jin, D | 1 |
| Guo, H | 1 |
| Bu, SY | 1 |
| Zhang, Y | 1 |
| Hannaford, J | 1 |
| Mashek, DG | 1 |
| Chen, X | 1 |
| Choi, JH | 1 |
| Banks, AS | 1 |
| Kamenecka, TM | 1 |
| Busby, SA | 1 |
| Chalmers, MJ | 1 |
| Kumar, N | 1 |
| Kuruvilla, DS | 1 |
| Shin, Y | 1 |
| He, Y | 1 |
| Bruning, JB | 1 |
| Marciano, DP | 1 |
| Cameron, MD | 1 |
| Laznik, D | 1 |
| Jurczak, MJ | 1 |
| Schürer, SC | 1 |
| Vidović, D | 1 |
| Shulman, GI | 2 |
| Spiegelman, BM | 1 |
| Griffin, PR | 1 |
| Stumvoll, M | 1 |
| Häring, HU | 1 |
| Yu, JG | 1 |
| Javorschi, S | 1 |
| Hevener, AL | 1 |
| Kruszynska, YT | 1 |
| Norman, RA | 1 |
| Sinha, M | 1 |
| Olefsky, JM | 1 |
| Dove, A | 1 |
| Sugiyama, Y | 1 |
| Nambi, V | 1 |
| Hoogwerf, BJ | 1 |
| Sprecher, DL | 1 |
| Larsen, TM | 1 |
| Toubro, S | 1 |
| Astrup, A | 1 |
| Banerjee, RR | 2 |
| Lazar, MA | 2 |
| Lebovitz, HE | 1 |
| Satoh, J | 1 |
| Dagogo-Jack, S | 1 |
| Buchanan, TA | 1 |
| Fonseca, V | 1 |
| Hollenberg, NK | 1 |
| Wellen, KE | 1 |
| Uysal, KT | 1 |
| Wiesbrock, S | 1 |
| Yang, Q | 1 |
| Chen, H | 1 |
| Hotamisligil, GS | 1 |
| Cheng, AY | 1 |
| Fantus, IG | 1 |
| Cariou, B | 1 |
| Capitaine, N | 1 |
| Le Marcis, V | 1 |
| Vega, N | 1 |
| Béréziat, V | 1 |
| Kergoat, M | 1 |
| Laville, M | 1 |
| Girard, J | 1 |
| Vidal, H | 1 |
| Burnol, AF | 1 |
| Urich, E | 1 |
| Petersen, KF | 1 |
| Ranganathan, G | 1 |
| Pokrovskaya, I | 1 |
| Yao-Borengasser, A | 2 |
| Phanavanh, B | 2 |
| Lecka-Czernik, B | 1 |
| Rasouli, N | 2 |
| Hartge, MM | 1 |
| Kintscher, U | 1 |
| Unger, T | 1 |
| Varma, V | 1 |
| Bodles, AM | 1 |
| Lee, MJ | 1 |
| Starks, T | 1 |
| Kern, LM | 1 |
| Spencer, HJ | 1 |
| McGehee, RE | 1 |
| Fried, SK | 1 |
| Arakawa, K | 1 |
| Inamasu, M | 1 |
| Matsumoto, M | 1 |
| Okumura, K | 1 |
| Yasuda, K | 1 |
| Akatsuka, H | 1 |
| Kawanami, S | 1 |
| Watanabe, A | 1 |
| Homma, K | 1 |
| Saiga, Y | 1 |
| Ozeki, M | 1 |
| Iijima, I | 1 |
| Fürnsinn, C | 1 |
| Brunmair, B | 1 |
| Meyer, M | 1 |
| Neschen, S | 1 |
| Furtmüller, R | 1 |
| Roden, M | 1 |
| Kühnle, HF | 1 |
| Nowotny, P | 1 |
| Schneider, B | 1 |
| Waldhäusl, W | 1 |
| Kasuga, M | 1 |
| Hunabiki, A | 1 |
| Morita, S | 1 |
| Yanase, T | 1 |
| Hamaguchi, T | 1 |
| Nakajima, H | 1 |
| Hanafusa, T | 1 |
| Matsuzawa, Y | 1 |
| Oguma, Y | 1 |
| Kataoka, K | 1 |
| Emilsson, V | 1 |
| O'Dowd, J | 1 |
| Wang, S | 1 |
| Liu, YL | 1 |
| Sennitt, M | 1 |
| Heyman, R | 1 |
| Cawthorne, MA | 1 |
| Steppan, CM | 1 |
| Bailey, ST | 1 |
| Bhat, S | 1 |
| Brown, EJ | 1 |
| Wright, CM | 1 |
| Patel, HR | 1 |
| Ahima, RS | 1 |
| Yakubu-Madus, FE | 1 |
| Stephens, TW | 1 |
| Johnson, WT | 1 |
| Rocchi, S | 1 |
| Auwerx, J | 1 |
| Hara, K | 1 |
| Kubota, N | 1 |
| Tobe, K | 1 |
| Terauchi, Y | 1 |
| Miki, H | 1 |
| Komeda, K | 1 |
| Tamemoto, H | 1 |
| Yamauchi, T | 1 |
| Hagura, R | 1 |
| Ito, C | 1 |
| Akanuma, Y | 1 |
| Kadowaki, T | 1 |
| Hu, B | 1 |
| Ellingboe, J | 1 |
| Gunawan, I | 1 |
| Han, S | 1 |
| Largis, E | 1 |
| Li, Z | 1 |
| Malamas, M | 1 |
| Mulvey, R | 1 |
| Oliphant, A | 1 |
| Sum, FW | 1 |
| Tillett, J | 1 |
| Wong, V | 1 |
| Castro Cabezas, M | 1 |
| Halkes, CJ | 1 |
| Erkelens, DW | 1 |
| Boelsterli, UA | 1 |
| Bedoucha, M | 1 |
| Camejo, G | 1 |
| Ljung, B | 1 |
| Oakes, N | 1 |
| Montague, CT | 1 |
| Sidell, RJ | 1 |
| Cole, MA | 1 |
| Draper, NJ | 1 |
| Desrois, M | 1 |
| Buckingham, RE | 1 |
| Clarke, K | 1 |
| Legro, RS | 1 |
| Buch, HN | 1 |
| Baskar, V | 1 |
| Barton, DM | 1 |
| Kamalakannan, D | 1 |
| Akarca, C | 1 |
| Singh, BM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation[NCT04455932] | 476 participants (Anticipated) | Interventional | 2022-01-31 | Recruiting | |||
| Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)[NCT00227110] | Phase 4 | 55 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance[NCT00108615] | Phase 4 | 48 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Relationship Between Obesity and Periodontal Disease[NCT02508415] | 62 participants (Actual) | Interventional | 2013-02-28 | Completed | |||
| Effectiveness of the Treatment With Dapagliflozin and Metformin Compared to Metformin Monotherapy for Weight Loss on Diabetic and Prediabetic Patients With Obesity Class III[NCT03968224] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2018-07-07 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
26 reviews available for 2,4-thiazolidinedione and Obesity
| Article | Year |
|---|---|
Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis.
Topics: Adult; Glucagon-Like Peptide-1 Receptor; Humans; Network Meta-Analysis; Non-alcoholic Fatty Liver Di | 2023 |
The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups.
Topics: Adolescent; Asia; Bariatric Surgery; Carcinoma, Hepatocellular; Chenodeoxycholic Acid; Child; Diet; | 2018 |
Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management.
Topics: Amyloid; Bariatric Surgery; Diabetes Mellitus; Diet, Reducing; Dipeptidyl-Peptidase IV Inhibitors; E | 2010 |
Glitazones: clinical effects and molecular mechanisms.
Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; | 2002 |
[Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
Topics: Animals; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents | 2002 |
A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia.
Topics: Angiotensin-Converting Enzyme Inhibitors; Female; Humans; Hyperinsulinism; Hypertension; Hypertrigly | 2002 |
PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Recept | 2003 |
Resistin: molecular history and prognosis.
Topics: Amino Acid Sequence; Animals; Gene Expression Regulation; Glucocorticoids; Glucose; Hormones, Ectopi | 2003 |
The relationship of obesity to the metabolic syndrome.
Topics: Adiponectin; Adipose Tissue; Blood Proteins; Body Constitution; Humans; Hypoglycemic Agents; Hypolip | 2003 |
[Insulin-sensitizing agents: metformin and thiazolidinedione derivatives].
Topics: Adipocytes; Adiponectin; Cyclic AMP-Dependent Protein Kinases; Diabetes Complications; Diabetes Mell | 2003 |
Ethnic disparities in type 2 diabetes: pathophysiology and implications for prevention and management.
Topics: Blood Circulation; Diabetes Mellitus, Type 2; Environmental Exposure; Female; Genetic Predisposition | 2003 |
Pancreatic beta-cell loss and preservation in type 2 diabetes.
Topics: Animals; Blood Glucose; Cell Count; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycem | 2003 |
Effect of thiazolidinediones on body weight in patients with diabetes mellitus.
Topics: Adipose Tissue; Body Weight; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Diabetes Melli | 2003 |
Considerations for management of fluid dynamic issues associated with thiazolidinediones.
Topics: Body Fluids; Body Weight; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 2; Di | 2003 |
[Insulin resistance: the adipose tissue in the focus].
Topics: Adipocytes; Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hyperplasia; Hypertrophy; Hypoglycemi | 2005 |
Etiology of insulin resistance.
Topics: Diabetes Mellitus, Type 2; Glucose Transporter Type 4; Humans; Hypoglycemic Agents; Insulin Receptor | 2006 |
Endothelial dysfunction and its role in diabetic vascular disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Hu | 2006 |
[Etiology and therapy of insulin resistance].
Topics: Animals; Arteriosclerosis; Biguanides; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertens | 1999 |
[Physiological function of peroxisome proliferator-activated receptor].
Topics: Animals; Blood Cells; Cell Differentiation; Cell Division; Colonic Neoplasms; Diabetes Mellitus, Typ | 1999 |
[Insulin resistance and cytokine, cytokine receptor].
Topics: Adipocytes; Animals; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Obesity; Receptors, Tumo | 2000 |
[Obesity, insulin resistance and the implication of thiazolidinediones].
Topics: Adipose Tissue; Diabetes Mellitus; Fatty Acids, Nonesterified; Humans; Hypoglycemic Agents; Insulin | 2000 |
Peroxisome proliferator-activated receptor gamma, the ultimate liaison between fat and transcription.
Topics: Adipose Tissue; Cell Differentiation; Diabetes Mellitus, Type 2; Humans; Leptin; Obesity; Receptors, | 2000 |
Obesity and free fatty acids: double trouble.
Topics: Chylomicrons; Coronary Artery Disease; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hyperlipid | 2001 |
Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Liver; Mice; Obesity; Receptors, Cytopla | 2002 |
Pharmacological treatment of insulin resistance in obesity.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Hypoglycemic Agents; Insulin Res | 2001 |
Polycystic ovary syndrome. Long term sequelae and management.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Contraceptives, Oral; Diabetes Mellitus, Type 2; Diag | 2002 |
3 trials available for 2,4-thiazolidinedione and Obesity
| Article | Year |
|---|---|
Effect of pioglitazone treatment on brown adipose tissue volume and activity and hypothalamic gliosis in patients with type 2 diabetes mellitus: a proof-of-concept study.
Topics: Adipose Tissue, Brown; Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fl | 2019 |
Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.
Topics: Adipose Tissue; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, N | 2009 |
The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
Topics: Adiponectin; Adult; Animals; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gluc | 2002 |
24 other studies available for 2,4-thiazolidinedione and Obesity
| Article | Year |
|---|---|
Novel thiazolidinedione analog reduces a negative impact on bone and mesenchymal stem cell properties in obese mice compared to classical thiazolidinediones.
Topics: Animals; Bone Marrow Stromal Antigen 2; Glucose; Glutamine; Humans; Hypoglycemic Agents; Insulin; Me | 2022 |
Natural human genetic variation determines basal and inducible expression of
Topics: Adipocytes; Adipose Tissue; Amidohydrolases; Animals; Gene Expression; Gene Expression Regulation; G | 2019 |
Insulin resistance is mechanistically linked to hepatic mitochondrial remodeling in non-alcoholic fatty liver disease.
Topics: Animals; Blood Glucose; Cardiolipins; Citric Acid Cycle; Diabetes Mellitus, Type 2; Fatty Acids; Hep | 2021 |
PPARγ deacetylation dissociates thiazolidinedione's metabolic benefits from its adverse effects.
Topics: Acetylation; Adipose Tissue, White; Animals; Body Weight; Energy Metabolism; Female; Hypoglycemic Ag | 2018 |
Efficacy of habitual exercise for improving lipid profiles depends on the PPRAγ genotype in Japanese males.
Topics: Asian People; Diet, High-Fat; Erythrocytes; Exercise; Fatty Acids; Genotype; Humans; Insulin Resista | 2014 |
Increasing adipocyte lipoprotein lipase improves glucose metabolism in high fat diet-induced obesity.
Topics: Adipocytes; Animals; Diet, High-Fat; Female; Glucose; Humans; Insulin Resistance; Lipoprotein Lipase | 2015 |
Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-gamma activation and function in lipid homeostasis and energy expenditure.
Topics: Acute-Phase Proteins; Adipocytes; Adipose Tissue, Brown; Animals; Dietary Fats; Energy Metabolism; H | 2011 |
Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue, White; Animals; Biphenyl Compounds; Body Fluids; Chloroceb | 2011 |
Seeking sweet relief for diabetes.
Topics: Behavior Control; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diet; Exe | 2002 |
Interaction of tumor necrosis factor-alpha- and thiazolidinedione-regulated pathways in obesity.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Drug Interactions; Hypoglycemic Agents; Insulin | 2004 |
Thiazolidinedione-induced congestive heart failure.
Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Obesity; S | 2004 |
Increased adipose tissue expression of Grb14 in several models of insulin resistance.
Topics: 3T3 Cells; Adaptor Proteins, Signal Transducing; Adipocytes; Adipose Tissue; Animals; Carrier Protei | 2004 |
The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment.
Topics: Adipocytes; Adipose Tissue; Adult; Aged; Animals; Diacylglycerol O-Acyltransferase; Fatty Acid Synth | 2006 |
Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation.
Topics: Abdominal Fat; Biomarkers; Biopsy; Body Mass Index; Cytokines; Gene Expression; Glucose Intolerance; | 2007 |
Novel benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents. Synthesis and structure-activity relationships.
Topics: Animals; Benzopyrans; Benzoxazoles; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglyc | 1997 |
Chronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolism.
Topics: Animals; Biological Transport; Body Weight; Cell Line; Deoxyglucose; Glucose; In Vitro Techniques; I | 1999 |
The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat.
Topics: Adipose Tissue, Brown; Animals; Body Weight; Carrier Proteins; Eating; Ion Channels; Membrane Protei | 2000 |
The hormone resistin links obesity to diabetes.
Topics: 3T3 Cells; Adipocytes; Amino Acid Sequence; Animals; Base Sequence; Chromosomes, Human, Pair 19; Clo | 2001 |
The hormone resistin links obesity to diabetes.
Topics: 3T3 Cells; Adipocytes; Amino Acid Sequence; Animals; Base Sequence; Chromosomes, Human, Pair 19; Clo | 2001 |
The hormone resistin links obesity to diabetes.
Topics: 3T3 Cells; Adipocytes; Amino Acid Sequence; Animals; Base Sequence; Chromosomes, Human, Pair 19; Clo | 2001 |
The hormone resistin links obesity to diabetes.
Topics: 3T3 Cells; Adipocytes; Amino Acid Sequence; Animals; Base Sequence; Chromosomes, Human, Pair 19; Clo | 2001 |
Lipid lowering explains the insulin sensitivity enhancing effects of a thiazolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione.
Topics: Animals; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Clamp Technique; Insulin; Insulin Resis | 2000 |
The role of PPARgamma as a thrifty gene both in mice and humans.
Topics: Adipose Tissue; Animals; Case-Control Studies; Diabetes Mellitus, Type 2; Dietary Fats; Humans; Hype | 2000 |
2,4-Thiazolidinediones as potent and selective human beta3 agonists.
Topics: Adrenergic beta-3 Receptor Agonists; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hum | 2001 |
A treatment for Mr WP: thiazolidinediones after troglitazone.
Topics: Aged; Animals; Body Mass Index; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glycated Hem | 2002 |
Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Heart; Heart Rate; Hypoglycemic Agents; Insulin | 2002 |
Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes.
Topics: Adult; Aged; Body Mass Index; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Drug T | 2002 |